The Wave of Innovation
Cardio Diagnostics’ revolutionary AI-driven coronary heart disease (CHD) tests have achieved a major milestone by securing two dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) codes: 0440U for the AI-driven CHD detection test, PrecisionCHD, and 0439U for the AI-driven CHD event risk assessment test, Epi+Gen CHD. Approved by the American Medical Association (AMA), these codes, effective April 1, 2024, are a game-changer, ushering in a new era for payer billing and payment for these innovative tests.
The Challenge of Heart Disease
Every year, heart attacks affect over 805,000 Americans, occurring at a staggering rate of one every 40 seconds. Heart disease, the foremost cause of death for both men and women, claimed the lives of more than 695,000 Americans in 2021, illustrating the magnitude of the problem. The most common type of heart disease, coronary heart disease (CHD), leads to over 375,000 deaths annually and incurs approximately $239.9 billion in associated medical costs, as reported by the CDC in its heart disease fact sheet.
Revolutionizing Heart Attack Prevention
Enter PrecisionCHD; the pioneering integrated genetic-epigenetic test for CHD detection and personalized insights, striving to avert heart attacks and enhance outcomes. This blood-based test leverages the power of artificial intelligence, alongside personalized genetic and epigenetic data, to sensitively detect CHD. By providing a non-invasive, scalable, and accessible solution, PrecisionCHD is a crucial tool for timely interventions and care management, crucially targeting underserved and minority populations.
Embracing the Future
The advent of dedicated CPT PLA codes for PrecisionCHD and Epi+Gen CHD marks a turning point in Cardio Diagnostics’ journey. By enabling precision diagnostics and empowering preventive care, these codes signify a decisive stride in achieving reimbursement from federal and private payers. With Cardio Diagnostics’ commitment to democratizing access to advanced cardiovascular solutions, the fight against the leading cause of death in the United States is set to be transformed.
Ultimately, Cardio Diagnostics’ breakthrough is not merely a business milestone; it signifies a potential shift in combating the scourge of heart disease, with ramifications beyond the realm of finance, shining a beacon of hope for individuals and society at large.
Photo by National Cancer Institute on Unsplash.
